In this video, Matthew Callstrom, MD, PhD discusses the risk of collecting system injury with microwave ablation and how central renal tumors can be effectively treated.  | Read More
Results of a new study showed that AFP categories agreed moderately with mRECIST outcomes and yielded accurate prognostic prediction in patients with unresectable hepatocellular carcinoma and AFP levels ≥400 ng/mL treated with chemoembolization. | Read More
A concentrated dose of anti-CEA CAR-T cells administered precisely at the site of a solid tumor by Pressure-enabled Drug Delivery (PEDD) is safe, with encouraging clinical responses, according to the results of a phase 1b clinical trial. | Read More
In patients with ultrasound-invisible early stage hepatocellular carcinoma, the combined therapy of conventional transarterial chemoembolization followed by fluoroscopy-guided radiofrequency ablation was safe and effective resulting in less local tumor progression and time to progression. | Read More
A nomogram including 6 pre-Y90 radioembolization (RAE) parameters predicted overall survival (OS) post-RAE in patients with colorectal cancer liver metastases. | Read More

Spotlight

In this video, Matthew Callstrom, MD, PhD discusses the risk of collecting system injury with microwave ablation and how central renal tumors can be effectively treated. 
In this video, Alda Tam, MD discusses the benefits of ablation in cases involving osteoid osteomas, pain palliation, and disease control.
When talking to hospitals and oncologists about the benefits of having a full-time interventional radiology (IR) faculty, it is important to highlight the work related value units (wRVUs) that can be brought in from a clinical prospective doing procedures, according to a presentation from Sarah White, MD, MS, FSIR at the Symposium on Clinical Interventional Oncology.